BRCA2 and Familial prostate cancer: In a hospital-based series (n=263) of prostate cancer patients with early ages at diagnosis (⩽55 years) in the UK, Edwards et al (2003) reported a prevalence of germline protein-truncating BRCA2 mutations of 2.3% (95%CI 0.8–5.0%).